von Willebrand Disease  
 

REFERENCES

  1. Rodeghiero F, Castaman G, Dini E.  Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood 1987;69: 454-459.
  1. Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, Ingerslev J, Lee CA, Lillicrap D, Mannucci PM, Mazurier C, Meyer D, Nichols WL, Nishino M, Peake IR, Rodeghiero F, Schneppenheim R, Ruggeri ZM, Srivastava A, Montgomery RR, Federici AB, the Working Party on von Willebrand Disease Classification.  Update on the pathophysiology and classification of von Willebrand disease:  a report of the Subcommittee on von Willebrand Factor. J Thromb Haemost 2006; 4:  2103–14
  1. Federici, A. and P. Mannuccio Mannucci (2007). "Management of inherited von Willebrand disease in 2007." Annals of Medicine 39(5): 346-358.
  1. Rodeghiero F, Castaman G. (2005) von Willebrand disease: epidemiology. In CA Lee, EE Berntorp and WK Hoots (Eds).  Textbook of Hemophilia.  Oxford: Blackwell, 2005: 265-271.
  1. Nichols W, Hutlin M, James A, Manco-Johnson M, Montgomery R, Ortel T. The Diagnosis, Evaluation, and Management of von Willebrand Disease. US Department of Health and Human Services, National Institutes of Health, National Heart Lung and Blood Institute 2007:1-112.
  1. Berntorp E and Petrini P. Long-term prophylaxis in von Willebrand disease. Blood Coagul Fibrin 2005;16 Suppl 1:S23-6.
  1. Nilsson IM, Berntorp E, Löfquist T, Pettersson H.  Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B.  J Intern Med 1992;232(1):25-32.
  1. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, Ingram JD, Manco-Johnson ML, Funk S, Jacobson L, Valentino LA, Hoots WK, Buchanan GR, DiMichele D, Recht M, Brown D, Leissinger C, Bleak S, Cohen A, Mathew P, Matsunaga A, Medeiros D, Nugent D, Thomas GA, Thompson AA, McRedmond K, Soucie JM, Austin H, and Evatt BL.  Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia.  N Engl J Med 2007;357(6):535-44.
  1. Berntorp E and Abshire T for the von Willebrand Disease Prophylaxis Network.  The von Willebrand Disease Prophylaxis Network: exploring a treatment concept. J Thromb Haemost 2006; 4(11):2511-2
Previous  
1 2 3 4 5

Would you like more information?   You are encouraged to contact Sharyne Donfield or Joel Bowen at the coordinating center (Rho, Inc., Chapel Hill, NC, USA) or members of the Steering Committee.

Funding for  the VWD PN and the VIP study is provided through an unrestricted grant by CSL Behring: www.cslbehring.com